WuXi Buys Genomics-Analysis Firm
WuXi PharmaTech currently participates in the NGS market through its WuXi Genome Center, a CLIA-certified lab that provides NGS services for discovery, clinical and diagnostics applications. In addition to CRO services, WuXi also offers antibodies, proteins and other reagents for life science research as a result of its purchase of Abgent (see IBO 10/15/11). Last year, it established the WuXi Biosciences consumables brand.
Shanghai, China 1/9/15—WuXi PharmaTech, a provider of lab and manufacturing services for drug and medical-device R&D, has acquired NextCODE Health for $65 million in cash. NextCODE provides a genome sequence–analysis platform for clinicians and researchers, including access to the largest clinical-genetics–reference database, creating a system developed at population scale, according to WuXi. “This new venture of WuXi NextCODE Genomics will create important new genomic and bioinformatic products and services to help make personalized treatment and medicine a reality. It will also enable doctors to provide better treatments to patients,” stated WuXi PharmaTech Chairman and CEO Dr. Ge Li. The company also stated that it broadens its offerings from pharmaceutical, biotech and medical-device companies to doctors and patients.
